These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 21194598)

  • 1. Sterile abscess formation in response to two separate branded long-acting gonadotropin-releasing hormone agonists.
    Miller BS; Shukla AR
    Clin Ther; 2010 Sep; 32(10):1749-51. PubMed ID: 21194598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sterile abscess formation associated with depot leuprorelin acetate therapy for central precocious puberty.
    Johnson SR; Nolan RC; Grant MT; Price GJ; Siafarikas A; Bint L; Choong CS
    J Paediatr Child Health; 2012 Mar; 48(3):E136-9. PubMed ID: 21564386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The histrelin implant: a novel treatment for central precocious puberty.
    Hirsch HJ; Gillis D; Strich D; Chertin B; Farkas A; Lindenberg T; Gelber H; Spitz IM
    Pediatrics; 2005 Dec; 116(6):e798-802. PubMed ID: 16322137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and treatment patterns with histrelin acetate subcutaneous implants vs. leuprolide injections in children with precocious puberty: a real-world study using a US claims database.
    Silverman LA; Han X; Huang H; Near AM; Hu Y
    J Pediatr Endocrinol Metab; 2021 Aug; 34(8):961-969. PubMed ID: 34147047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist.
    Yeshaya A; Kauschansky A; Orvieto R; Varsano I; Nussinovitch M; Ben-Rafael Z
    Acta Obstet Gynecol Scand; 1998 Mar; 77(3):327-9. PubMed ID: 9539281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and outcomes of precocious puberty: an update.
    Fuqua JS
    J Clin Endocrinol Metab; 2013 Jun; 98(6):2198-207. PubMed ID: 23515450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
    Daskivich TJ; Oh WK
    Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leuprolide acetate: a drug of diverse clinical applications.
    Wilson AC; Meethal SV; Bowen RL; Atwood CS
    Expert Opin Investig Drugs; 2007 Nov; 16(11):1851-63. PubMed ID: 17970643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results.
    Mericq V; Lammoglia JJ; Unanue N; Villaroel C; Hernández MI; Avila A; Iñiguez G; Klein KO
    Clin Endocrinol (Oxf); 2009 Nov; 71(5):686-90. PubMed ID: 19302581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonists: gonadorelin, leuprolide and nafarelin.
    Pace JN; Miller JL; Rose LI
    Am Fam Physician; 1991 Nov; 44(5):1777-82. PubMed ID: 1835275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The treatment of precocious puberty.
    Wheeler MD; Styne DM
    Endocrinol Metab Clin North Am; 1991 Mar; 20(1):183-90. PubMed ID: 1827623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leuprolide acetate (Fensolvi) for central precocious puberty.
    Med Lett Drugs Ther; 2021 Sep; 63(1634):e1-e2. PubMed ID: 34606489
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoimmune thyroiditis during leuprolide acetate treatment.
    Eyal O; Rose SR
    J Pediatr; 2004 Mar; 144(3):394-6. PubMed ID: 15001954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central precocious puberty in a girl with Williams syndrome: the result of treatment with GnRH analogue.
    Utine GE; Alikasifoglu A; Alikasifoglu M; Tuncbilek E
    Eur J Med Genet; 2006; 49(1):79-82. PubMed ID: 16473313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
    Mizutani T; Sakata M; Terakawa N
    Int J Fertil Menopausal Stud; 1995; 40(2):106-11. PubMed ID: 7599657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
    Lee PA; Klein K; Mauras N; Lev-Vaisler T; Bacher P
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3153-9. PubMed ID: 24926950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent anaphylaxis associated with gonadotropin-releasing hormone analogs: case report and review of the literature.
    Lam C; Tjon J; Hamilton J; Ahmet AH
    Pharmacotherapy; 2006 Dec; 26(12):1811-5. PubMed ID: 17125443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.